The gold standard treatment for Anterior Cruciate Ligament injury is reconstruction (ACL-R). Graft failure is the concern and ensuring a durable initial graft with rapid integration is crucial. Graft augmentation with implantable devices (internal brace reinforcement) is a technique purported to reduce the risk of rupture and hasten recovery. We aim to compare the short-term outcome of ACL-R using augmented hamstring tendon autografts (internally braced with neoligament) and non-augmented hamstring autografts. This was a retrospective cohort study comparing augmented and non-augmented ACL-R. All procedures were performed in a single centre using the same technique. The Knee injury and Osteoarthritis Outcome Score [KOOS] was used to assess patient-reported outcomes.Abstract
Background
Methods
The UK National Joint Registry(NJR) has not reported total knee replacement (TKR)survivorship based on design philosophy alone, unlike its international counterparts. We report outcomes of implant survivorship based on design philosophy using data from NJR's 2020 annual report. All TKR implants with an identifiable design philosophy from NJR data were included. Cumulative revision data for cruciate-retaining(CR), posterior stabilised(PS), mobile-bearing(MB) design philosophies was derived from merged NJR data. Cumulative revision data for individual brands of implants with the medial pivot(MP) philosophy were used to calculate overall survivorship for this design philosophy. The all-cause revision was used as the endpoint and calculated to 15 years follow-up with Kaplan-Meier curves.Abstract
Background and study aim
Materials and methods
The gold standard treatment for Anterior Cruciate Ligament injury is reconstruction (ACL-R). Graft augmentation with suture tape (internal brace) are techniques purported to reduce the risk of rupture and hasten recovery. Our aim was to assess the short-term outcome of ACL-R using fibre tape augmented and non-augmented hamstring tendon grafts. This was a retrospective comparative study looking at augmented and non-augmented ACL-R. All procedures were performed by a single surgeon in a single centre using the same technique. The Knee injury and Osteoarthritis Outcome Score [KOOS] was used to assess patient-reported outcomes.Abstract
Background
Methods
Medial patellofemoral ligament (MPFL) reconstructions are often performed using gracilis autografts, this can be associated with donor site morbidity and complications. The use of synthetic material can circumvent a harvest operation and have previously been demonstrated to be effective in other types of reconstructive procedures and may be effective in MPFL reconstruction. We report our experience and clinical results with the use of FiberTape (FT) in MPFL reconstruction and compare it to the same surgical technique using standard autografts. Data were collected prospectively in 50 MPFL reconstructions. The first 27 underwent reconstruction using autograft; the following 23 patients were treated with FT. All patients were clinically and radiologically assessed and underwent pre- and post-operative scoring using the Kujala score, Bartlett score, Modified Tegner activity rating scale, SF 12 score and Lysholm score. Statistical significance was tested between groups using ANOVA with repeated measures.Background of study
Materials and Methods
Oxford Medial Unicompartmental Knee Replacement (OMUKR) is a well-established treatment option for isolated medial compartment arthritis, with good patient reported outcome measures (PROMs). We present our results of the Oxford Domed Lateral Unicompartmental Knee Replacement (ODLUKR) to establish if patients benefit as much as with OMUKR. Retrospective review of prospectively collected data of a single surgeon series of consecutive UKR from 2007 to 2014 were collated with a minimum 2 years follow-up. PROMs data were collected using pre- and post-operative Oxford Knee Scores (OKS) (best score of 48). One hundred and twenty-eight OMUKR and 27 ODLUKR were performed in the study period. There was no significant difference in the age at time of surgery, but there were significantly more women in the ODLUKR group (74% vs 53%). There was no significant difference in pre-op OKS between the groups (OMUKR = 16/48; ODLUKR = 20/48), or the improvement in OKS post-op (OMUKR = 19 points; ODLUKR = 17 points). One ODLUKR was revised to Total Knee Replacement (TKR) for pain. There were three (11.1%) bearing dislocations, which were treated with thicker bearing exchange, with no subsequent problems. There were no bearing dislocations in the OMUKR. Four OMUKR were revised to TKR due to pain. The overall implant survivorship was 96.3% for ODLUKR and 96.9% for OMUKR. ODLUKR is a good treatment option for isolated lateral compartment arthritis and gives results equivalent to OMUKR. There is, however, an increased risk of bearing dislocation so should be performed by a high volume UKR surgeon.
Intramuscular injections of botulinum neuro toxin A (BoNT-A) have been a cornerstone in the treatment of spasticity for the last two decades. In India, the treatment is now offered to children with spastic cerebral palsy (CP). However, despite its use, the evidence for its functional effects is limited and inconclusive. The objective of this study is to determine whether BoNT-A makes walking easier in children with CP. We hypothesize that injections with BoNT-A will not reduce energy cost during walking, improve walking capacity, reduce pain or improve self-perceived performance and satisfaction. Between the period of 2012 and 2014, 35 children with spastic CP less than 10 years of age were included. The patients were classified according to their gross motor function classification system (GMFCS) and their pre-and post-injection gait analysis were performed. Spasticity assessed by Modified Ashworth Score [MAS]. Trained parents were utilised for the post injection physiotherapy as these children will be more complaint to them. GMFCS and MAS scoring done every three months till one year follow up. Therapeutically, effect was found in 90% of the patients, an average duration of the medical effect was 6–12 months. The improvement in GMFC functional score in serial measurements was seen in these patients though some deterioration in spasticity scores at one year. Despite mild recurrence in spasticity, majority maintained independent (42%) or assisted ambulation (48%) at one year. No major side effects occurred. Botox may prove a useful adjuvant in conservative management of the spasticity of cerebral palsy. Apart from being very cost effective in these financially deprived populations, successful management with these injections may allow delay of surgical intervention until the child is older and at less risk of possible complications, including the need for repeated surgical procedures.
